Several breakthroughs in cancer immunotherapy have emerged, including advances that enhance CAR T-cell therapy efficacy. Researchers at the San Raffaele-Telethon Institute have engineered cellular communication systems to improve CAR-T infiltration into glioblastoma, an aggressive brain cancer. Further, studies reveal novel methods to arm CAR T cells with additional immunoactivating proteins at tumor sites to target solid tumors more effectively. Immunotherapeutic approaches in glioblastoma and hepatocellular carcinoma also show promising results, including dual checkpoint blockade and vaccination therapy strategies to boost patient outcomes.